Medcura Secures $22.4 Million to Revolutionize Surgical Hemostasis
April 6, 2024, 9:32 am
Medcura, a trailblazer in surgical hemostasis, has locked in a hefty $22.4 million in convertible debt to propel the development of its groundbreaking LifeGel™ Absorbable Hemostatic Gel. Led by CEO Jim Buck and Executive Chair Larry Tiffany, Medcura is on a mission to transform the $2.8 billion biosurgery market with its innovative products. The company's no-swell technology is set to revolutionize bleeding control in spinal surgery, offering a safer and more effective solution. With a strong focus on disruptive innovation, Medcura is poised to make a significant impact in the medical field.